Welcome & framing the conversation
Chairs: Claire Harrison & John Mascarenhas

Part 1: Where have we been and where are we going

• Current endpoint landscape in MPN clinical trials: Prithviraj Bose

Part 2: Patient-centered outcomes in MPNs: What matters most

• Reflections of a PV patient after living for 15 years with the disease: Werner Zinkand
• Beyond spleen and symptoms: Evolving MPN clinical trials and endpoints to improve patient outcomes with real-world evidence: David Shoultz

Panel discussion 1: What constitutes meaningful benefit in MPNs today?
Chairs: Claire Harrison, John Mascarenhas & Ruben Mesa
Panellists: Ronald Hoffman, Prithviraj Bose, David Shoultz, Alison Moliterno, Wener Zinkand

Break

Part 3: Regulatory considerations in endpoint development

• Endpoints in MPN and MDS: Regulatory perspective: Tanya Wroblewski

Q & A for Part 3: Regulatory considerations in endpoint development   

Part 4: Aligning scientific innovation, patient experience, and regulatory standards
Chairs: Gabriela Hobbs & Francesco Passamonti

• Role of molecular endpoints: Jennifer O’Sullivan
• How best to integrate symptoms and QoL: beat ruxolitinib or non-inferior: Ruben Mesa
• Durability of spleen response: Francesco Passamonti
• Anemia benefit: Abdulraheem Yacoub
• Abolishing venesection vs complete haematological response: Marina Kremyanskaya

Panel discussion 2: Aligning scientific innovation, patient experience, and regulatory standards
Chairs: Gabriela Hobbs & Francesco Passamonti
Panellists: Jennifer O’Sullivan, Ruben Mesa, David Shoultz, Werner Zinkand

Working group session close and next steps
Claire Harrison & John Mascarenhas

iwMPN welcome reception

Welcome and introduction
Claire Harrison & Amer Zeidan

Keynote talk 1
Updates in classification for MDS, MDS/MPN and MPN: Robert Hasserjian

Session 1: Innovation
Chairs: Sanam Loghavi & Francesca Palandri

• Emerging novel targets: a focus on G6B: Beth Psaila
• Are we ready to mainline AI?: Sanam Loghavi
• Wearable devices data and novel approaches to digital data capture: Patrick Harrington

Panel discussion

Break

Session 2: Targeted therapies: CALR, JAK-selective and beyond
Chairs: Shannon Elf & Jason Gotlib

• Latest on CALR biology: Shannon Elf
• Targeting mutant CALR with INCA033989 latest data: John Mascarenhas
• Type II JAK inhibitors: AJ1-11095 – what should we expect: Gabriela Hobbs
• Flonoltinib JAK/CDK/FLT3: Bing Li

Panel discussion

Session 3: Frontline myelofibrosis combination strategies
Chairs: Pankit Vachhani & TBC

• Pelabresib: Raajit Rampal
• Selinexor: Nikolai Podoltsev
• Navtemadlin: Pankit Vachhani
• What treatment for a low-risk MF in 2026: Alex Coltoff

Panel discussion

Lunch

Session 4: Second-line myelofibrosis: Sequencing and positioning
Chairs: Marina Kremyanskaya & Srinivas Tantravahi

• Nuvisertib: Joseph Scandura
• Imetelstat: Andrew Kuykendall
• Tasquinimod in myelofibrosis: Lucia Masarova
• Elritercept: Claire Harrison
• Luspatercept: Francesco Passamonti
• DISC-0974: Rupali Bhave

Panel discussion

Break

Session 5: Polycythaemia vera and essential thrombocythemia: Emerging agents and targets
Chairs: Steffen Koschmieder & Lindsay Rein

• Is ruxolitinib ready for front line therapy in PV?: Steffen Koschmieder
• Bomedemstat in ET and PV: Lindsay Rein
• Where is the unmet need in ET?: Douglas Tremblay
• Rusfertide in PV: where does it fit in an evolving treatment landscape?: Andrew Kuykendall

Panel discussion

Session 6: Systemic mastocytosis: Rapidly evolving targeted therapy
Chairs: William Shomali & Lindsay Rein

• Considerations on how to evolve systemic mastocytosis response criteria in the KIT inhibitor era: Jason Gotlib
• The evolving landscape of therapy for indolent systemic mastocytosis: Lindsay Rein
• Updates in the treatment of AdvSM: Daniel DeAngelo

Panel discussion

Day 2 conclusions & close
Claire Harrison & John Mascarenhas

iwMDS welcome reception

Welcome to Day 3
John Mascarenhas & Amer Zeidan

Keynote talk 2

icMDS: progress and future directions: Amer Zeidan

Session 7: What is the current best practice in higher-risk MDS?
Chairs:Rami Komrokji & Yazan Madanat

• Debate: Venetoclax still has a role for venetoclax in higher-risk MDS
  • Yes: Yasmin Abaza
  • No: Mikkael Sekeres
• How I will treat higher-risk MDS in 2027: Yazan Madanat
• Evolving antibodies in management of higher risk MDS: Amer Zeidan
• Lessons learned from a decade of higher-risk MDS trials: Maximilian Stahl
• Ethical issues in over- and under-treatment of older MPN/MDS patients: Gregory Abel
• Strategies for bridging HR-MDS patients to allogeneic transplantation: Klaus Metzeler

Panel discussion

Keynote talk 3
Exciting progress and major updates in BPDCN for 2026 and beyond: Naveen Pemmaraju

Session 8: From CHIP to blast phase
Chairs: Kelly Bolton & Naveen Pemmaraju

• Clonal evolution in MPN how often to screen, when to act and what to do: Paola Guglielmelli
• Accelerated and blast phase management including fit and unfit patients: Vikas Gupta

Panel discussion

Break

Session 9: From CHIP to MDS
Chairs: Maximilian Stahl & Lynette Chee

• The role of NK cells in the progression from CH to MDS: Simona Colla
• Biological insights on marrow microenvironment driving progression in CH: Katharina Götze
• Using the CHIVE registry to better understand risk of CH: Michael Savona
• How to design studies for CCUS and CHIP: Uma Borate

Panel discussion

Session 10: MDS/MPN overlaps and VEXAS
Chairs: Hetty Caraway & TBC

• JAK inhibitors and evolving therapies for MDS/MPN overlaps: Abdulraheem Yacoub
• Novel therapies in VEXAS: Carmelo Gurnari
• Systemic mastocytosis: 2026 updates: William Shomali

Panel discussion

Lunch

Session 11: CMML
Chairs: Michael Savona & Douglas Tremblay

• Improving prognostication in CMML: Luca Lanino
• Oral HMAs for CMML: Daniel Wiseman
• Novel therapies for CMML: Mrinal Patnaik
• CMML response criteria: Somedeb Ball

Panel discussion

Session 12: Diagnosis, classification and prognostication in MDS and MDS/MPN
Chairs: Valeria Santini & Matteo Della Porta

• Incorporation of flow cytometry in diagnosis and classification of MDS: Arjan van de Loosdrecht
• Prognostication in TP53-mutated MDS – is there any “good” subtype?: Tariq Kewan
• How can AI help in MDS prognostication and management?: Matteo Della Porta
• Development of the icMDS-PRO score: Fabio Efficace

Panel discussion 

Break

Session 13: What is the role of allo-SCT for the treatment of MDS?
Chairs: Olatoyosi Odenike & TBC

• Debate: Should we transplant TP53-mutated MDS patients?
  • No: Alain Mina
  • Yes: Talha Badar
•  Which MDS patients should be transplanted in the era of PTCy?: Amy DeZern
• Does non-transplant cellular therapy have a future in MDS?: Mohamed Kharfan Dabaja

Panel discussion

Keynote talk 4  

Clinical development of lenalidomide in LR-MDS a lesson in drug development: Alan List

Day 3 conclusions & close 
John Mascarenhas & Amer Zeidan

Faculty dinner

Welcome to Day 4
Amer Zeidan

Session 14: What are the right endpoints for future MDS clinical trials?
Chairs: Amer Zeidan & Valeria Santini

• What are the right endpoints for lower-risk and higher-risk MDS trials?: Rami Komrokji
• Peripheral blood CR as a new endpoint in clinical trials: Lisa Pleyer
• Industry perspective on drug approval for MDS: Harold Keer
  
• FDA views on drug approval for MDS: Nina Kim
• Statistical perspectives and trial designs for MDS: Radhika Avadhani
• Clinical trial reporting in MDS: Andrew Brunner

Panel discussion

Session 15: Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 1)
Chairs: Amer Zeidan & Steven Gore

• CTEP views on use for novel agents in MDS: Steven Gore
• Important US MDS trials: Olatoyosi Odenike
• The Canadian plan for MDS trials: Rena Buckstein

Panel discussion

Break

Session 16: Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 2)
Chairs: Astrid Olsnes & Ioannis Kotsianidis

• The Chinese plan for MDS trials: Bing Li
• The Scandinavian plan for MDS trials: Astrid Olsnes
• The Greek plan for MDS trials: Ioannis Kotsianidis
• The Australian plan for MDS trials: Lynette Chee

Panel discussion

Lunch

Session 17: Novel targets in MDS
Chairs: Michael Savona & Valeria Santini

• What are the next promising targets for higher-risk MDS?: Hetty Carraway
• What are the next promising targets for lower-risk MDS?: Elizabeth Griffiths
• Targeting the TGF pathway and inflammation in MDS: Maria Diez-Campelo

Panel discussion

Session 18: How should we think about MRD in MDS?
Chairs: Maximilian Stahl & Coleman Lindsley

• Flow cytometry for MRD in MDS: Arjan van de Loosdrecht
• Molecular MRD in MDS – What can we learn from longitudinal deep sequencing in higher-risk MDS?: Coleman Lindsley
• Clinical application and limitations of measurable residual disease in MDS: Andrew Brunner

Panel discussion

Meeting summary and close
Amer Zeidan